Related references
Note: Only part of the references are listed.Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells
Owen D. Stechishin et al.
NEURO-ONCOLOGY (2013)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Current clinical development of PI3K pathway inhibitors in glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2012)
EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Hui-Wen Lo
Current Molecular Pharmacology (2012)
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion
Walter Stummer et al.
ACTA NEUROCHIRURGICA (2011)
Current Concepts and Management of Glioblastoma
Matthias Preusser et al.
ANNALS OF NEUROLOGY (2011)
eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206
Yan Cheng et al.
CANCER RESEARCH (2011)
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Filip Janku et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma
Kenneth L. Pitter et al.
PLOS ONE (2011)
TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation
Nadia Boufaied et al.
ANTI-CANCER DRUGS (2010)
PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
Aranapakam M. Venkatesan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Concurrent Radiotherapy and Temozolomide Followed by Temozolomide and Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme
John D. Hainsworth et al.
CANCER (2010)
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
Andrew C. Hsieh et al.
CANCER CELL (2010)
Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma
Oren J. Becher et al.
CANCER RESEARCH (2010)
Reversing HOXA9 Oncogene Activation by PI3K Inhibition: Epigenetic Mechanism and Prognostic Significance in Human Glioblastoma
Bruno M. Costa et al.
CANCER RESEARCH (2010)
Therapeutic targeting of EGFR in malignant gliomas
Fei Ye et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor
Robert Mallon et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
C. A. Sparks et al.
ONCOGENE (2010)
Automated Network Analysis Identifies Core Pathways in Glioblastoma
Ethan Cerami et al.
PLOS ONE (2010)
Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma
Qi-Wen Fan et al.
SCIENCE SIGNALING (2010)
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
P. Cao et al.
BRITISH JOURNAL OF CANCER (2009)
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Nathan T. Ihle et al.
CANCER RESEARCH (2009)
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Jean-Sebastien Guillamo et al.
CLINICAL CANCER RESEARCH (2009)
Antitumor Activity of a Novel Antisense Oligonucleotide Against Akt1
Heejeong Yoon et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Teri N. Kreisl et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Georg Karpel-Massler et al.
MOLECULAR CANCER RESEARCH (2009)
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
Gary L. Gallia et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors
Li Li et al.
NEURO-ONCOLOGY (2009)
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
M-A Westhoff et al.
ONCOGENE (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Oncogenic EGFR Signaling Networks in Glioma
Paul H. Huang et al.
SCIENCE SIGNALING (2009)
Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
Jeffrey D. Carson et al.
BIOCHEMICAL JOURNAL (2008)
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Bing-Hua Jiang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2008)
Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway
Frederic Stauffer et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Nelson Rhodes et al.
CANCER RESEARCH (2008)
Epidermal growth factor receptor and glioblastoma multiforme:: molecular basis for a new approach
Cristobal Belda-Iniesta et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death
Vivian Egler et al.
CLINICAL CANCER RESEARCH (2008)
Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas
Will R. Voelzke et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Li Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Brain Cancer Stem Cells Display Preferential Sensitivity to Akt Inhibition
Christine E. Eyler et al.
STEM CELLS (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
Chuan-Hsiang Huang et al.
SCIENCE (2007)
Epidemiology of brain tumors
James L. Fisher et al.
NEUROLOGIC CLINICS (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma
John K. Wiencke et al.
NEURO-ONCOLOGY (2007)
Molecularly targeted therapy for malignant glioma
Sith Sathornsumetee et al.
CANCER (2007)
PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion
X. Liu et al.
ONCOGENE (2007)
Phosphatase and tensin homologue deficiency in giloblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir
Zibin Jiang et al.
CANCER RESEARCH (2007)
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo
A. Iwamaru et al.
ONCOGENE (2007)
Radiotherapy for glioblastoma in the elderly
Florence Keime-Guibert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E. Franceschi et al.
BRITISH JOURNAL OF CANCER (2007)
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Jann N. Sarkaria et al.
MOLECULAR CANCER THERAPEUTICS (2007)
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling
Paul M. Campbell et al.
CANCER RESEARCH (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
PIK3CA alterations in primary (de novo) and secondary glioblastomas
Daisuke Kita et al.
ACTA NEUROPATHOLOGICA (2007)
Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas
M. Kelly Nicholas et al.
CLINICAL CANCER RESEARCH (2006)
Human cancers express a mutator phenotype
Jason H. Bielas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Isoform specific inhibitors of PI3 kinase in glioma
Qi-Wen Fan et al.
CELL CYCLE (2006)
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme
Gary L. Gallia et al.
MOLECULAR CANCER RESEARCH (2006)
Novel mutations of epidermal growth factor receptor in localized prostate cancer
Diah A. Douglas et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-Deficient and PTEN-intact glioblastoma cells
Maria Y. Wang et al.
CANCER RESEARCH (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study
Timothy F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
L. Doherty et al.
NEUROLOGY (2006)
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells
Lorena de la Pena et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
D Koul et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Changing paradigms - An update on the multidisciplinary management of malignant glioma
Roger Stupp et al.
ONCOLOGIST (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Cancer-specific mutations in PIK3CA are oncogenic in vivo
AG Bader et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells
JJ Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
AB Lassman et al.
CLINICAL CANCER RESEARCH (2005)
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 30H-kinase
T Nobukuni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas
CB Knobbe et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2005)
hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase
MP Byfield et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo
H Momota et al.
CANCER RESEARCH (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
An expanding role for mTOR in cancer
DA Guertin et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
Y Samuels et al.
CANCER CELL (2005)
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Y Luo et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Functional analysis of PIK3CA gene mutations in human colorectal cancer
T Ikenoue et al.
CANCER RESEARCH (2005)
PIK3CA mutations in glioblastoma multiforme
C Hartmann et al.
ACTA NEUROPATHOLOGICA (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Waltraud X. Schulze et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
SY Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
VK Puduvalli et al.
APOPTOSIS (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Current management of glioblastoma multiforme
SA Grossman et al.
SEMINARS IN ONCOLOGY (2004)
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas
DK Broderick et al.
CANCER RESEARCH (2004)
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism
N Pore et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316
EJ Meuillet et al.
ONCOLOGY RESEARCH (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
A Chakravarti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas
M Mizoguchi et al.
BRAIN PATHOLOGY (2004)
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells
SO Rahaman et al.
ONCOGENE (2002)
Akt regulates growth by directly phosphorylating Tsc2
CJ Potter et al.
NATURE CELL BIOLOGY (2002)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components
B Actor et al.
GENES CHROMOSOMES & CANCER (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
BHP Zhou et al.
NATURE CELL BIOLOGY (2001)
PKB/AKT: Functional insights from genetic models
MP Scheid et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization
T Watanabe et al.
GYNECOLOGIC ONCOLOGY (2001)
Regulation of translation initiation by FRAP/mTOR
AC Gingras et al.
GENES & DEVELOPMENT (2001)
The class II phosphoinositide 3-kinase C2α is activated by clathrin and regulates clathrin-mediated membrane trafficking
I Gaidarov et al.
MOLECULAR CELL (2001)
Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85α regulatory subunit
K Ueki et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
TOR, a central controller of cell growth
T Schmelzle et al.
CELL (2000)
Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site
A Toker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Phosphoinositide signaling and the regulation of membrane trafficking in yeast
G Odorizzi et al.
TRENDS IN BIOCHEMICAL SCIENCES (2000)
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
EC Holland et al.
NATURE GENETICS (2000)
Share Paper
